Sabbatini P - Search Results

1

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. Among authors: sabbatini p. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.

2

Salvage therapy for ovarian cancer.

Sabbatini P, Spriggs D. Sabbatini P, et al. Oncology (Williston Park). 1998 Jun;12(6):833-43; discussion 844-6, 848, 851. Oncology (Williston Park). 1998. PMID: 9644684 Free article. Review.

3

Chemotherapy in gynecologic cancer.

Sabbatini P, Aghajanian C, Spriggs D. Sabbatini P, et al. Curr Opin Oncol. 1998 Sep;10(5):429-33. doi: 10.1097/00001622-199809000-00010. Curr Opin Oncol. 1998. PMID: 9800113 Review.

4

Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma.

Makhija S, Sabbatini P, Barakat RR. Makhija S, et al. Among authors: sabbatini p. Curr Opin Obstet Gynecol. 1999 Feb;11(1):23-7. doi: 10.1097/00001703-199901000-00005. Curr Opin Obstet Gynecol. 1999. PMID: 10047959 Review.

5

Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.

Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M. Husain A, et al. Among authors: sabbatini p. Gynecol Oncol. 1999 Apr;73(1):96-101. doi: 10.1006/gyno.1998.5317. Gynecol Oncol. 1999. PMID: 10094887 Clinical Trial.

6

Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.

Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R. Makhija S, et al. Among authors: sabbatini p. Gynecol Oncol. 2000 Oct;79(1):28-32. doi: 10.1006/gyno.2000.5890. Gynecol Oncol. 2000. PMID: 11006026 Clinical Trial.

7

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D. Hensley ML, et al. Among authors: sabbatini p. Gynecol Oncol. 2001 Jun;81(3):485-9. doi: 10.1006/gyno.2001.6185. Gynecol Oncol. 2001. PMID: 11371143

8

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.

Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, Chi D, Spriggs DR. Hensley ML, et al. Among authors: sabbatini p. Gynecol Oncol. 2001 Sep;82(3):464-9. doi: 10.1006/gyno.2001.6299. Gynecol Oncol. 2001. PMID: 11520141

9

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.

Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Barakat RR, et al. Among authors: sabbatini p. J Clin Oncol. 2002 Feb 1;20(3):694-8. doi: 10.1200/JCO.2002.20.3.694. J Clin Oncol. 2002. PMID: 11821450

10

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR. Dizon DS, et al. Among authors: sabbatini p. J Clin Oncol. 2002 Mar 1;20(5):1238-47. doi: 10.1200/JCO.2002.20.5.1238. J Clin Oncol. 2002. PMID: 11870166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page